BCL2 and glioblastoma: Although the existing literature mostly discusses the Bcl-2 family and beclin-1 in isolation, our manuscript systematically frames this interaction as a dynamic regulatory switch at the intersection of survival signalling and therapeutic reprogramming in GBM.